The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study

Nakamura, Toshio; Osawa, Mitsuharu; Itoh, Makoto; Yamaguchi, Hiromichi; Iinuma, Norio; Hayakawa, Yutaka; Suzuki, Hitoshi; Kamisaki, Toshiaki; Nishikawa, Masahiko

doi:10.1007/s00774-012-0372-2

Cited by 7 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another 12‐week long observational study (17.5 mg/week risedronate) with 1363 Japanese females, the greatest improvement concerned the dimension of ‘pain/discomfort’ in QOL (Nakamura et al, 2012). In a 3‐year post‐marketing study of once monthly 75 mg risedronate in 285 patients with low back pain (presence/absence, but not evaluated by VAS or QOL), the proportion of patients with low back pain decreased gradually by 30.77% at 36 months (Soen et al, 2020).…”

Section: Resultsmentioning

confidence: 99%

Osteoporosis treatment and pain relief: A scoping review

Pickering¹,

Javier

Malochet³

et al. 2023

European Journal of Pain

View full text Add to dashboard Cite

Background and ObjectiveAnti‐osteoporosis (OP) drugs have been suggested to contribute to pain reduction during OP management. This scoping review aimed at mapping the literature on pain relief with anti‐OP drugs in OP treatment.Databases and Data TreatmentMedline, Pubmed and Cochrane databases were searched by two reviewers with keywords combinations. Randomized controlled and real‐life English studies, pain as an endpoint, antiosteoporosis drugs were inclusion criteria. Case reports, surveys, comment letters, conference abstracts, animal studies and grey literature were excluded. Predetermined data were extracted by two reviewers and disagreement solved through discussion.ResultsA total of 130 articles were identified, 31 publications were included, 12 randomized clinical trials and 19 observational studies. Pain reduction was assessed by different tools: Visual Analogue Scale, Verbal Rating Scale, Facial Scale or as a domain of quality of life questionnaires including Short form 8, 36, mini‐OP, Japanese OP, Qualeffo, Roland Morris Disability questionnaires. Collective data show that anti‐OP drugs may display an analgesic effect that may be linked to the local mode of action of drugs on bone and consecutive modulation of pain sensitization. The methodology of the studies showed a heterogeneity of endpoints, comparators, statistical approaches and follow‐up duration.ConclusionConsidering the limitations of the literature, there is a need for more rigorous trials and larger real‐life studies taking into account the recommendations published for research in rheumatology and in pain medicine. The identification of responders, patient subtypes, and of analgesic‐effect doses would allow optimization and individualization for pain relief in patients with OP.Significance StatementThis scoping review shows that anti‐OP drugs may improve pain and quality of life of patients with OP. The heterogeneity in design, choice of endpoints, methodology, comparators and follow‐up duration of included randomized clinical trials and real‐life studies does not allow so far to identify a predominant antiosteoporosis drug or an optimal dosage for pain relief. These gaps need to be addressed and warrant further research in the future for optimizing pain improvement in the course of OP drug treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Osteoporosis treatment and pain relief: A scoping review

Pickering¹,

Javier

Malochet³

et al. 2023

European Journal of Pain

View full text Add to dashboard Cite

show abstract

“…Other studies have reported on the increase t EQ‐5D utility score after initiation of osteoporosis treatment – . Nakamura et al reported that a weekly dose of risedronate improved the EQ‐5D score in Japanese women with osteoporosis. Langdahl et al reported that the improvement in the EQ‐5D score with teriparatide treatment specifically resulted from a decrease in back pain.…”

Section: Discussionmentioning

confidence: 99%

Denosumab Treatment Improved Health‐Related Quality of Life in Osteoporosis: A Prospective Cohort Study

et al. 2019

View full text Add to dashboard Cite

Improving patient health‐related quality of life (HRQOL) and prevention of bone fracture are important components of the treatment of osteoporosis. Our aim in this study was to evaluate the effect of denosumab treatment in improving HRQOL among patients with osteoporosis. Our analysis was based on 332 patients with osteoporosis, followed for 24 months. All patients received denosumab (60 mg) subcutaneously every 6 months. Bone mineral density (BMD) was assessed at the distal radius, with serum concentration of calcium, phosphate, P1NP, and TRACP5b also measured. HRQOL assessment included pain (visual analogue scale [VAS]) and the EQ‐5D questionnaire. A multivariate analysis was performed to identify the possible confounders associated with deterioration in the EQ‐5D utility score in response to denosumab treatment. Denosumab treatment yielded a 3.4% increase in BMD at 24 months. Serum levels of TRACP5b and P1NP decreased significantly, from baseline, at 6 months, with no effect on calcium and phosphate levels. Pain VAS and EQ‐5D utility score improved significantly, from baseline, at 6 months, with the EQ‐5D utility score correlating with the BMD at all time points of measurement over the 24‐month period of observation. Knee osteoarthritis and multiple comorbidities were significantly associated with a worse HRQOL in response to denosumab treatment. Denosumab treatment increased BMD, with improvements in BMD correlating with improved HRQOL, supporting a possible benefit of using denosumab for the treatment of osteoporosis. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

show abstract

A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions

et al. 2014

View full text Add to dashboard Cite

This study aimed to statistically combine multiple health state utility values (HSUVs) reported in the literature for patients with osteoporosis and osteoporotic fractures. Fracture events were associated with decrements in HSUVs which differed between fracture sites. We have provided summary values for use in future health economics analyses in osteoporosis. Osteoporotic fractures have high financial and health burden. Economic evaluations on osteoporotic fracture prevention have been frequently performed in past decades. One of the challenges in the economic evaluations was to identify consistent health state utility values (HSUVs) to use for osteoporotic fracture-related conditions. The objective of this study was to determine summary measures of multiple HSUVs reported in the literature for patients with osteoporosis and osteoporotic fractures. We performed a systematic review, meta-analysis and meta-regression of published literature that reported HSUVs for osteoporotic fracture-related conditions. There were 62 studies representing 142,477 patients included. In total, 362 HSUVs were identified: 106 for pre-fracture; 89 for post-hip fracture; 130 for post-vertebral fracture and 37 for post-wrist fracture. The pooled HSUVs, using a random-effects model were 0.76 (95% CI 0.75, 0.77, I (2) = 0.99) for pre-fracture; 0.57 (95% CI 0.52, 0.63, I (2) =1) for post-hip fracture; 0.59 (95% CI 0.55, 0.62, I (2) = 0.99) for post-vertebral facture and 0.72 (95% CI 0.67, 0.78, I (2) = 1) for post-wrist fracture. Heterogeneities were addressed through meta-regression. HSUVs immediately following hip, vertebral and wrist fractures were 0.31, 0.44 and 0.61, respectively. Patients' HSUVs improved over time following fracture events: HSUVs for the first year after hip, vertebral and wrist fractures were 0.59, 0.55 and 0.78, respectively; and 0.66, 0.66 and 0.81 for subsequent years. Fractures were associated with significant decrements in HSUVs. This study provides a standard set of HSUVs that can be used in health economic assessments in osteoporosis.

show abstract

The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study

Cited by 7 publications

References 36 publications

Osteoporosis treatment and pain relief: A scoping review

Osteoporosis treatment and pain relief: A scoping review

Denosumab Treatment Improved Health‐Related Quality of Life in Osteoporosis: A Prospective Cohort Study

A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions

Contact Info

Product

Resources

About